The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Δ-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway
Abstract
In this study, we show that Δ-9-tetrahydrocannabinol (THC), the major psychoactive component of marijuana, suppresses host immune reactivity against lung cancer. In two different weakly immunogenic murine lung cancer models, intermittent administration of THC (5 mg/kg, four times/wk i.p. for 4 wk) led to accelerated growth of tumor implants compared with treatment with diluent alone. In contrast to our findings in immunocompetent mice, THC did not affect tumor growth in tumor-bearing SCID mice. The immune inhibitory cytokines, IL-10 and TGF-β, were augmented, while IFN-γ was down-regulated at both the tumor site and in the spleens of THC-treated mice. Administration of either anti-IL-10- or anti-TGF-β-neutralizing Abs prevented the THC-induced enhancement in tumor growth. Both APC and T cells from THC-treated mice showed limited capacities to generate alloreactivity. Furthermore, lymphocytes from THC-treated mice transferred the effect to normal mice, resulting in accelerated tumor growth similar to that seen in the THC-treated mice. THC decreased tumor immunogenicity, as indicated by the limited capacity for tumor-immunized, THC-treated mice to withstand tumor rechallenge. In vivo administration of a specific antagonist of the CB2 cannabinoid receptor also blocked the effects of THC. Our findings suggest the THC promotes tumor growth by inhibiting antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. R., & Coffman, R. L. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.001045 · Cited by 7,692
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 2×
“Understanding of the potential pathways for cannabinoid-mediated immune modulation has been enhanced by discovery of receptors with high affinity for cannabinoids (12, 76).”
BackgroundStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
Groux, H., O'Garra, A., Bigler, M., Rouleau, M., Antonenko, S., de Vries, J. E., & Roncarolo, M. G. (1997) · Nature · doi:10.1038/39614 · Cited by 3,588
IL-10 inhibits cytokine production by activated macrophages
Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., & O’Garra, A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.11.3815 · Cited by 2,888
REGULATION OF IMMUNE RESPONSES BY TGF-β
Letterio, J. J., & Roberts, A. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.137 · Cited by 1,890
IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells
Fiorentino, D. F., Zlotnik, A., Vieira, P., Mosmann, T. R., Howard, M., Moore, K. W., & O’Garra, A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.10.3444 · Cited by 1,865
Preferential Formation of Benzo[ a ]pyrene Adducts at Lung Cancer Mutational Hotspots in P53
Denissenko, M. F., Pao, A., Tang, M.-S., & Pfeifer, G. P. (1996) · Science · doi:10.1126/science.274.5286.430 · Cited by 1,650
Cytokines Induce the Development of Functionally Heterogeneous T Helper Cell Subsets
O'Garra, A. (1998) · Immunity · doi:10.1016/s1074-7613(00)80533-6 · Cited by 1,533
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,249
Cited by
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Indeed, THC enhances breast and lung cancer growth and metastasis by suppressing CB2 receptor-mediated antitumor immune responses (Zhu et al., 2000; McKallip et al., 2005) and can also lead to increased susceptibility to infections with various pathogens such as herpes simplex virus, Legionella…”
BackgroundGillison, M. L., D'Souza, G., Westra, W., Sugar, E., Xiao, W., Begum, S., & Viscidi, R. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn025 · Cited by 1,543
Cannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1188 · Cited by 703
Neuronal Control of Skin Function: The Skin as a Neuroimmunoendocrine Organ
Roosterman, D., Goerge, T., Schneider, S. W., Bunnett, N. W., & Steinhoff, M. (2006) · Physiological Reviews · doi:10.1152/physrev.00026.2005 · Cited by 665
Cannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
Howlett, A. C. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00060-6 · Cited by 535
The cannabinoid system and immune modulation
Klein, T. W., Newton, C., Larsen, K., Lu, L., Perkins, I., Nong, L., & Friedman, H. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0303101 · Cited by 524
Molecular Pathology of Head and Neck Cancer: Implications for Diagnosis, Prognosis, and Treatment
Pai, S. I., & Westra, W. H. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092158 · Cited by 508
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice
Steffens, S., Veillard, N. R., Arnaud, C., Pelli, G., Burger, F., Staub, C., Zimmer, A., Frossard, J.-L., & Mach, F. (2005) · Nature · doi:10.1038/nature03389 · Cited by 472
Cabral, G. A., & Griffin-Thomas, L. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409000957 · Cited by 408
Towards the use of cannabinoids as antitumour agents
Velasco, G., Sánchez, C., & Guzmán, M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3247 · Cited by 372
A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme
Guzmán, M., Duarte, M. J., Blázquez, C., Ravina, J., Rosa, M. C., Galve-Roperh, I., Sánchez, C., Velasco, G., & González-Feria, L. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603236 · Cited by 365
Microbial Infections, Immunomodulation, and Drugs of Abuse
Friedman, H., Newton, C., & Klein, T. W. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.2.209-219.2003 · Cited by 338
Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines
Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., & Parolaro, D. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.061002 · Cited by 271
Anticancer Mechanisms of Cannabinoids
Velasco, G., Sánchez, C., & Guzmán, M. (2016) · Current Oncology · doi:10.3747/co.23.3080 · Cited by 265
Cannabis use and risk of lung cancer: a case–control study
Aldington, S., Harwood, M., Cox, B., Weatherall, M., Beckert, L., Hansell, A., Pritchard, A., Robinson, G., & Beasley, R. (2008) · European Respiratory Journal · doi:10.1183/09031936.00065707 · Cited by 264
Hashibe, M., Morgenstern, H., Cui, Y., Tashkin, D. P., Zhang, Z.-F., Cozen, W., Mack, T. M., & Greenland, S. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0330 · Cited by 256
Self-citationΔ9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells
Yuan, M., Kiertscher, S. M., Cheng, Q., Zoumalan, R., Tashkin, D. P., & Roth, M. D. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00370-3 · Cited by 234
“…production of T helper 1 (Th1)-associated cytokines, including IL-2, IL-12 and interferon-g (IFN-g), and increase the production of T helper 2 (Th2)-associated cytokines, including IL-4 and IL-10 (Newton et al., 1994; Klein et al., 2000; Zhu et al., 2000; Smith et al., 2000; Ouyang et al., 1998).”
BackgroundSelf-citationChang, Y., Lee, S. T., & Lin, W. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.1103 · Cited by 219
Cannabinoid-Induced Immune Suppression and Modulation of Antigen-Presenting Cells
Klein, T. W., & Cabral, G. A. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-005-9007-x · Cited by 172
Cannabinoid receptor systems: therapeutic targets for tumour intervention.
Jones, S., & Howl, J. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.6.749 · Cited by 13
“Targets (2003) 7(6) 755 interfere with immune defences against neoplasia [96,97], although reports of cannabinoids enhancing tumour growth by immunosuppressive mechanisms are limited [96].”
Background
Metadata
- Authors
- Zhu, L. X., Sharma, S., Stolina, M., Gardner, B., Roth, M. D., Tashkin, D. P., & Dubinett, S. M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-07-01
- Volume
- 165
- Issue
- 1
- Pages
- 373-380
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1670328913
- Cited by
- 252
- References
- 83
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.